GSK’s record-breaking 3.0 Bn USD fine for concealing adverse cardiac data on the diabetes drug Avandia, and FDA’s complicity in hiding the data is reviewed in this compelling article. Sadly, this remarkable fiasco has done little to preserve the reputation of the drug maker nor the FDA. And that the subject is being re-opened appears to be yet another bad judgement call. Ouch.
http://lnkd.in/UQ5zpx
linkedin post 2022-06-29 05:12:48
Nigel Fleming
September 21, 2022